BONE-MARROW TOXICITY CAUSED BY AZATHIOPRINE IN INFLAMMATORY BOWEL-DISEASE - 27 YEARS OF EXPERIENCE
BONE-MARROW TOXICITY CAUSED BY AZATHIOPRINE IN INFLAMMATORY BOWEL-DISEASE - 27 YEARS OF EXPERIENCE
复制标题
DOI：
10.1136/gut.34.8.1081
复制
发表时间：
1993-08-01
期刊：
影响因子：
24.5
通讯作者：
LENNARDJONES, JE
中科院分区：
文献类型：
--
作者：
CONNELL, WR;KAMM, MA;LENNARDJONES, JE
骨髓抑制是硫唑嘌呤治疗的一个重要且可能致命的并发症。一家医院对所有接受硫唑嘌呤治疗炎症性肠病超过 27 年的患者进行了血细胞计数检查。总共 739 名患者（422 名克罗恩病患者、284 名溃疡性结肠炎患者和 33 名不确定性结肠炎患者）接受了 2 mg/kg/天的硫唑嘌呤治疗，中位治疗时间为 12 。 1964 年至 1991 年间 5 个月（范围 0. 5-132）。在治疗期间每月进行一次全血细胞计数。 37 名患者（5%）出现骨髓毒性，因此停药或减少剂量。其中 32 名患者无症状，5 名出现症状。 28 名 (3-8%) 患者出现白细胞减少症（白细胞计数低于 3.0X10g/l），其中 9 名患者出现严重白细胞减少症（白细胞计数低于 3.0X10g/l）
Myelosuppression is an important and potentially lethal complication of azathioprine treatment. The blood count has been reviewed in all patients treated with azathioprine for inflammatory bowel disease over 27 years in one hospital. Altogether 739 patients (422 with Crohn's disease, 284 with ulcerative colitis, and 33 with indeterminate colitis) were treated with 2 mg/kg/day azathioprine for a median of 12 . 5 months (range 0 . 5-132) between 1964 and 1991. Full blood counts were performed monthly for the duration of treatment. In 37 patients (5%) who developed bone marrow toxicity, the drug was withdrawn or the dose reduced. Thirty two of these patients were asymptomatic and five developed symptoms. Leucopenia (white blood count less than 3.0X10g/l) occurred in 28 (3-8%) patients, in nine of whom it was severe (white blood count